Literature DB >> 35965176

Pyopneumothorax induced by rupture of pneumatocele after COVID-19: A case report.

Hanako Koda1, Ryusuke Sumiya2, Hideki Miyazaki3, Satoshi Nagasaka4.   

Abstract

Entities:  

Year:  2022        PMID: 35965176      PMCID: PMC9371946          DOI: 10.1016/j.asjsur.2022.07.142

Source DB:  PubMed          Journal:  Asian J Surg        ISSN: 1015-9584            Impact factor:   2.808


× No keyword cloud information.
To the editor, COVID-19 pneumonia can be accompanied by complications such as pneumothorax, pneumomediastinum, pleural effusion, pneumatocele, and empyema. Although these COVID-19 complications are relatively uncommon, they increase mortality and morbidity. Pneumatoceles are round-shaped cystic changes of the lung parenchyma. The cause of a pneumatocele may be infectious or non-infectious. Infected pneumatoceles may be caused by bacterial or viral infection. In contrast, non-infected pneumatoceles are caused by trauma, surgery, mechanical ventilation including continuous positive airway pressure and long-term administration of corticosteroids. Furthermore, intense inflammatory reactions and corticosteroid therapy during COVID-19 can be additional causes. Here we would like to share a rare case of a newly developed pneumatocele after COVID-19 infection that ruptured, producing pyopneumothorax. A 55-year-old man was treated as moderate COVID-19 pneumonia with remdesivir and corticosteroid. A month after the onset of COVID-19, moderate pneumothorax on the right, bilateral pulmonary cysts with fluid collection located in right segment 8 and left segment 9 respectively, and pleural effusion were detected on chest computed tomography (Fig. 1 a and b). He was diagnosed with bilateral pleurisy and right pneumothorax. The chest drain tube was placed in the right thoracic cavity, and antibiotic therapy was administered with hospitalization. However, during hospitalization, rupture of the pneumatocele in the right lung caused pyopneumothorax; therefore, he underwent thoracoscopic surgery on the right lung. Additionally, since he was an airplane pilot, thoracoscopic resection of the pneumatocele in the left lung was performed. Intraoperatively, there was loose adhesion throughout the entire thoracic cavity, and the pneumatocele was detected in segment 8 (Fig. 1c). Pathological findings showed inflammation of the lung parenchyma and pleura with lymphocyte infiltration and subpleural pulmonary cysts with endogenous hemorrhage (Fig. 1d). Phlegm culture detected staphylococcus aureus and streptococci, and bacterial cultures of pleural effusion and blood were negative. His postoperative course was uneventful and was discharged on the 8th day after the second surgery.
Fig. 1

Representative image from the computed tomography scan. Pulmonary cyst located in right segment 8 (yellow arrow), and moderate pneumothorax in right lung. (a) Pulmonary cyst located in left segment 9 (red arrow). (b) Intraoperative photograph showing the pneumatocele in the segment 8 of the right lower lobe. (c) Pathological image showing subpleural pulmonary cysts with endogenous hemorrhage. (d).

Representative image from the computed tomography scan. Pulmonary cyst located in right segment 8 (yellow arrow), and moderate pneumothorax in right lung. (a) Pulmonary cyst located in left segment 9 (red arrow). (b) Intraoperative photograph showing the pneumatocele in the segment 8 of the right lower lobe. (c) Pathological image showing subpleural pulmonary cysts with endogenous hemorrhage. (d). Several cases with pneumatoceles after COVID-19 were reported thus far. In this case, in addition to COVID-19 infection and long-term corticosteroid use, the phlegm cultures were positive for Streptococci or Staphylococcus aureus, which could contribute to the formation of pneumatocele. Approximately 85% of pneumatoceles resolve spontaneously. However, some patients with pneumatoceles complicated by infection, pneumothorax, or pneumomediastinum require additional therapy. Although antibiotic therapy or percutaneous drainage is often performed initially, some patients who fail to respond to conservative treatment require surgical resection. Lobectomy or pneumectomy are mainly performed to completely remove the infected area and prevent postoperative complications due to the presence of dense adhesions or uncomplicated fissures caused by inflammation. However, since the pneumatocele in this case was located in the lateral segment, we opted to perform partial resection to preserve pulmonary function. Herein, this case suggests that pneumatoceles with associated pneumothorax and empyema can even occur in patients after COVID-19 infection without a history of positive pressure ventilation, and thoracoscopic resection can be effectively performed.

Declaration of competing interest

None declared.
  5 in total

1.  Complicated pneumonias with empyema and/or pneumatocele in children.

Authors:  Valmir Kunyoshi; Daniele Cristina Cataneo; Antônio José Maria Cataneo
Journal:  Pediatr Surg Int       Date:  2005-12-16       Impact factor: 1.827

2.  Corticosteroid therapy for severe COVID-19 pneumonia: optimal dose and duration of administration.

Authors:  Wataru Matsuda; Tatsuya Okamoto; Tatsuki Uemura; Kentaro Kobayashi; Ryo Sasaki; Akio Kimura
Journal:  Glob Health Med       Date:  2020-06-30

3.  Pneumatocele formation in adult Escherichia coli pneumonia.

Authors:  M M Puri; A Srivastava; A K Jain; D Behera
Journal:  Ann Thorac Med       Date:  2011-04       Impact factor: 2.219

4.  The analysis of pleural complications of COVID-19 pneumonia

Authors:  Merve Şatır Türk; Irmak Akarsu; Ismail Tombul; Aykut Kankoç; Nur Dilvin Özkan; Elgun Valiyev; Muhammet Sayan; Ali Çelik; Ismail Cüneyt Kurul; Olgun Kadir Arıbaş; Abdullah Irfan Taştepe
Journal:  Turk J Med Sci       Date:  2021-12-13       Impact factor: 0.973

5.  Thoracic surgery outcomes for patients with Coronavirus Disease 2019.

Authors:  Stephanie H Chang; David Chen; Darien Paone; Travis C Geraci; Joshua Scheinerman; Costas Bizekis; Michael Zervos; Robert J Cerfolio
Journal:  J Thorac Cardiovasc Surg       Date:  2021-01-30       Impact factor: 5.209

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.